This Article Figures Only Full Text Full Text (PDF) View CVN News View Related Editorial Comment Online Appendix All Versions of this Article: j.jacc.2008.04.055v1 52/10/869    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Orasanu, G. Articles by Plutzky, J. Search for Related Content PubMed PubMed Citation Articles by Orasanu, G. Articles by Plutzky, J. Related Collections Related Article

EXPEDITED PUBLICATION

The Peroxisome Proliferator-Activated Receptor- Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-–Dependent Manner In Vitro and In Vivo in Mice

Gabriela Orasanu, MD^_*,, Ouliana Ziouzenkova, PhD^_*,, Pallavi R. Devchand, PhD^_*,, Vedika Nehra, MS^_*,, Osama Hamdy, MD^,, Edward S. Horton, MD^, and Jorge Plutzky, MD^_*,,_*

^_* Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
Clinical Research Center, Joslin Diabetes Center, Boston, Massachusetts
Harvard Medical School, Boston, Massachusetts

Manuscript received March 10, 2008; revised manuscript received April 22, 2008, accepted April 29, 2008.

^_* Reprint requests and correspondence: Dr. Jorge Plutzky, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB 742, Boston, Massachusetts 02115 (Email: jplutzky{at}rics.bwh.harvard.edu).

Objectives: Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)- agonist pioglitazone modulates inflammation through PPAR mechanisms.

Background: The thiazolidinediones (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPAR agonists used to treat type 2 diabetes (T2DM). Despite evidence for TZDs limiting inflammation and atherosclerosis, questions exist regarding differential responses to TZDs. In a double-blinded, placebo-controlled 16-week trial among recently diagnosed T2DM subjects (n = 34), pioglitazone-treated subjects manifested lower triglycerides and lacked the increase in soluble vascular cell adhesion molecules (sVCAM)-1 evident in the placebo group. Previously we reported PPAR but not PPAR agonists could repress VCAM-1 expression. Since both triglyceride-lowering and VCAM-1 repression characterize PPAR activation, we studied pioglitazone's effects via PPAR.

Methods: Pioglitazone effects on known PPAR responses—ligand binding domain activation and PPAR target gene expression—were tested in vitro and in vivo, including in wild-type and PPAR-deficient cells and mice, and compared with the effects of other PPAR (rosiglitazone) and PPAR (WY14643) agonists.

Results: Pioglitazone repressed endothelial TNF-induced VCAM-1 messenger ribonucleic acid expression and promoter activity, and induced hepatic IB in a manner dependent on both pioglitazone exposure and PPAR expression. Pioglitazone also activated the PPAR ligand binding domain and induced PPAR target gene expression, with in vitro effects that were most pronounced in endothelial cells. In vivo, pioglitazone administration modulated sVCAM-1 levels and IB expression in wild-type but not PPAR-deficient mice.

Conclusions: Pioglitazone regulates inflammatory target genes in hepatic (IB) and endothelial (VCAM-1) settings in a PPAR-dependent manner. These data offer novel mechanisms that may underlie distinct TZD responses.

Key Words: inflammation • VCAM-1 • PPAR

Abbreviations and Acronyms   ACO = acyl-CoA oxidase   BAEC = bovine aortic endothelial cells   EC = endothelial cell   FPG = fasting plasma glucose   GAPDH = glyceraldehyde-3-phosphate dehydrogenase   HbA1c = hemoglobin A1c   HDL = high-density lipoprotein   HSVEC = human endothelial cells isolated from saphenous vein   LBD = ligand binding domain   LDL = low-density lipoprotein   LPL = lipoprotein lipase   LPS = lipopolysacharide   PPAR = peroxisome proliferator-activated receptor   TG = triglyceride(s)   TNF = tumor necrosis factor   TZD = thiazolidinedione   T2DM = type 2 diabetes mellitus   VCAM = vascular cell adhesion molecule   2h-OGTT = 2-h plasma glucose 200 mg/dl during oral glucose tolerance testing

Related Article

Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor- Activation Make the Difference?

Ulrich Kintscher
J. Am. Coll. Cardiol. 2008 52: 882-884. [Full Text] [PDF]

This article has been cited by other articles:

				D. T. Chan, G. F. Watts, A. B. Irish, and G. K. Dogra Rosiglitazone does not improve vascular function in subjects with chronic kidney disease Nephrol. Dial. Transplant., November 1, 2011; 26(11): 3543 - 3549. [Abstract] [Full Text] [PDF]

				E. Castillero, M. P. Nieto-Bona, C. Fernandez-Galaz, A. I. Martin, M. Lopez-Menduina, M. Granado, M. A. Villanua, and A. Lopez-Calderon Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy Am J Physiol Endocrinol Metab, May 1, 2011; 300(5): E790 - E799. [Abstract] [Full Text] [PDF]

				J. Plutzky The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance Circ. Res., April 15, 2011; 108(8): 1002 - 1016. [Abstract] [Full Text] [PDF]

				M. E. Shaul, G. Bennett, K. J. Strissel, A. S. Greenberg, and M. S. Obin Dynamic, M2-Like Remodeling Phenotypes of CD11c+ Adipose Tissue Macrophages During High-Fat Diet-Induced Obesity in Mice Diabetes, May 1, 2010; 59(5): 1171 - 1181. [Abstract] [Full Text] [PDF]

				E. Erdmann and R. Wilcox Pioglitazone and mechanisms of CV protection QJM, April 1, 2010; 103(4): 213 - 228. [Abstract] [Full Text] [PDF]

				D. I. Lebovic, J. M. Mwenda, D. C. Chai, A. Santi, X. Xu, and T. D'Hooghe Peroxisome Proliferator-Activated Receptor-{gamma} Receptor Ligand Partially Prevents the Development of Endometrial Explants in Baboons: A Prospective, Randomized, Placebo-Controlled Study Endocrinology, April 1, 2010; 151(4): 1846 - 1852. [Abstract] [Full Text] [PDF]

				A. Higuchi, K. Ohashi, R. Shibata, S. Sono-Romanelli, K. Walsh, and N. Ouchi Thiazolidinediones Reduce Pathological Neovascularization in Ischemic Retina Via an Adiponectin-Dependent Mechanism Arterioscler Thromb Vasc Biol, January 1, 2010; 30(1): 46 - 53. [Abstract] [Full Text] [PDF]

				I. Tzoulaki, M. Molokhia, V. Curcin, M. P Little, C. J Millett, A. Ng, R. I Hughes, K. Khunti, M. R Wilkins, A. Majeed, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ, December 3, 2009; 339(dec03_1): b4731 - b4731. [Abstract] [Full Text] [PDF]

				U. Kintscher Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-{alpha} Activation Make the Difference? J. Am. Coll. Cardiol., September 2, 2008; 52(10): 882 - 884. [Full Text] [PDF]